Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp reported that non-employee director Leslye G. Katz acquired 85 Encompass Health Common Stock-equivalent RSUs at $0.00 per unit under a grant/award transaction. These RSUs were credited as dividend equivalents tied to a $0.19 per share common stock dividend, using a $109.88 closing price on July 15, 2026. Following this award, Katz’s direct holdings total 49,643 shares/units.
Encompass Health Corp director Joan E. Herman reported an automatic acquisition of 85 shares of common stock in the form of restricted stock units (RSUs). These RSUs were credited under outstanding award agreements in connection with the July 15, 2026 common stock dividend of $0.19 per share, when the stock’s closing price was $109.88. Following this dividend-equivalent RSU award, Herman directly holds 49,643 shares of Encompass Health common stock.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp reports that director Cain A. Hayes received a grant of 4 units of Encompass Health Common Stock on July 15, 2026. According to the award terms, these restricted stock units were credited as dividend equivalents following a $0.19 per-share dividend when the stock closed at $109.88. After this award, Hayes holds a total of 2,096 shares directly, reflecting routine, compensation-related accrual rather than an open-market purchase or sale.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received an automatic award of 29 restricted stock units (RSUs) tied to a common stock dividend paid on July 15, 2026. These RSUs were credited at a dividend of $0.19 per share and a closing price of $109.88, bringing his reported direct Encompass Health equity holdings to 20,349 units.
Encompass Health Corporation issued and sold $500 million of 5.875% Senior Notes due 2034 in a private offering, receiving about $491.2 million in net proceeds. The company plans to use this cash, along with existing cash on hand, to redeem at par $400 million of its 4.500% senior notes due 2028, repay $100 million outstanding under its revolving credit facility, and cover related fees and expenses.
The new notes are senior unsecured obligations, guaranteed on a senior unsecured basis by certain subsidiaries, and pay interest semiannually each June 1 and December 1 until maturity on June 1, 2034. The indenture includes optional redemption features, a change-of-control repurchase right at 101% of principal, and customary covenants and events of default, including cross-default and judgment thresholds of $100 million.
Encompass Health Corp EVP & CFO Douglas Coltharp reported a combination of option exercise and share sales in Encompass Health Common Stock. He exercised 27,694 shares from a non-qualified stock option at an exercise price of $32.94 per share and acquired the same number of common shares.
On the same date, he sold a total of 27,694 shares of common stock in open-market transactions at weighted average prices of about $106.83 and $107.28 per share, leaving 69,377 directly held shares. The option grant, originally exercisable until October 28, 2026, now has 0 options remaining after this exercise.
Indirect holdings reported after these transactions include 37,749 shares held by his spouse, 125,631 shares held by an irrevocable trust for the benefit of children, and 27,480 shares held by another irrevocable trust. A footnote states the option terms were adjusted under the 2016 Omnibus Performance Incentive Plan for the spin-off distribution of Enhabit, Inc.
Encompass Health Corporation has agreed to issue $500 million in aggregate principal amount of 5.875% senior notes due 2034 in a private offering, with closing expected on or about May 29, 2026, subject to the purchase agreement terms. The notes will be guaranteed on a senior unsecured basis by certain subsidiaries and sold to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S.
The company currently intends to use the net proceeds, together with cash on hand, to redeem at par $400 million of its outstanding 4.500% Senior Notes due 2028, repay $100 million under its senior secured revolving credit facility, and pay related fees and expenses. Encompass Health describes itself as the largest owner and operator of inpatient rehabilitation hospitals in the United States, with 175 hospitals in 39 states and Puerto Rico.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported an open-market sale of Encompass Health Common Stock. He sold 682 shares at a price of $104.56 per share on May 11, 2026, and held 24,755 shares directly after this transaction.